Previous research demonstrated that ATO at the concentration of 1 or 2 μΜ induces the degradation of BCR‐ABL1 in CML‐blast crisis cell line, K562 16. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.